Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RABBIT: Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3
NCT06814496Phase 2Recruiting
- Sponsor
- University of Arizona
- Start
- Sep 2025
- Primary completion
- May 2030
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 2, open-label trial of tarlatamab in melanoma, Medullary Thyroid Cancer (MTC), sinonasal undifferentiated carcinoma (SNUC) and 9 more (4 cohorts), sponsored by University of Arizona. Primary endpoint: Dose Limiting Toxicities up to 24 months. Started Sep 2025; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
melanomaMedullary Thyroid Cancer (MTC)sinonasal undifferentiated carcinoma (SNUC)esthesioneuroblastoma (ENB)bladder cancer
Beyond the preview
Go deeper on NCT06814496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06814496.